[ CancerWeb Home
| Comments
| Up One Level ]
Original Summaries of Selected CANCERLIT Records
OVX1, A Potential New Prognostic Marker for Prostate Cancer
Last modified on:
Tuesday, April 20, 1999 10:52:30
Copyright © 1994-2008, Information Ventures, Inc.
A potential new prognostic marker for prostate cancer is
OVX1, studied by a group at the University of Texas, M.D. Anderson
Cancer Center, in Houston (Xu; ICDB/95613763). OVX1 is monoclonal
antibody raised against a human ovarian carcinoma cell line. The
results in 114 cases of prostate cancer showed that 57% of the bone
marrow specimens had elevated OVX1 levels (greater than 7.2 U/ml).
In other experiments, OVX1 levels were about 2-fold higher in serum
samples from androgen-independent than from androgen-dependent
prostate cancer patients (p less than 0.001), suggesting that serum
OVX1 levels may be able to predict the progression of prostate
cancer, since this disease when it progresses typically becomes
androgen-independent. Serum OVX1 levels were inversely correlated
with survival rate of prostate cancer patients (p less than 0.001).
In addition, in cell-free supernatants from several human prostate
cancer lines, androgen-independent (DU-145 and PC-3), but not
androgen dependent (LNCaP and C-4) cell lines produced OVX1. These
data confirm an association of OVX1 with androgen-independent
prostate carcinoma, and suggest that it might serve as a potential
prognostic marker for human prostate cancer.
November, 1995
Copyright (c) 1994-2008, Information Ventures, Inc.
Mail us at: Customer-Service@infoventures.com
http://infoventures.com